Amgen’s decision to launch its Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns) biosimilars ‘at risk’ in the US during ongoing patent litigation has been rewarded by leading US insurer UnitedHealthcare. The owner of the OptumRx pharmacy benefit manager will from 1 October to give Mvasi and Kanjinti preferred coverage as specialty injectables under its commercial, community and Medicare Advantage plans.
From the same date, the insurer will for the same group of members prefer Sandoz’ Zarxio (filgrastim-sndz) to its rival biosimilar, Pfizer’s Nivestym (filgrastim-aafi), as well as to Teva’s Granix (tbo-filgrastim) follow-on